Madrigal Pharmaceuticals Inc. (MDGL)’s Financial Results Comparing With Idera Pharmaceuticals Inc. (NASDAQ:IDRA)

Both Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) and Idera Pharmaceuticals Inc. (NASDAQ:IDRA) are each other’s competitor in the Biotechnology industry. Thus the compare of their risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation.

Valuation & Earnings Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Madrigal Pharmaceuticals Inc. N/A 0.00 29.78M -2.13 0.00 Idera Pharmaceuticals Inc. N/A 105.25 62.66M -2.48 0.00 We can see in table 1 the earnings per share (EPS), gross revenue and valuation of Madrigal Pharmaceuticals Inc. and Idera Pharmaceuticals Inc.


Table 2 hightlights the net margins, return on equity and return on assets of the two companies. Net Margins Return on Equity Return on Assets Madrigal Pharmaceuticals Inc. 0.00% -9% -8.8% Idera Pharmaceuticals Inc. 0.00% -68.4% -60.4% Risk & Volatility

A 1.44 beta means Madrigal Pharmaceuticals Inc.’s volatility is 44.00% more than Standard and Poor’s 500’s volatility. Idera Pharmaceuticals Inc. has a 2.22 beta and it is 122.00% more volatile than Standard and Poor’s 500.


73.7 and 73.7 are the respective Current Ratio and a Quick Ratio of Madrigal Pharmaceuticals Inc. Its rival Idera Pharmaceuticals Inc.’s Current and Quick Ratios are 8.2 and 8.2 respectively. Madrigal Pharmaceuticals Inc. has a better chance of clearing its pay short and long-term debts than Idera Pharmaceuticals Inc.

Analyst Ratings

The next table highlights the shown recommendations and ratings for Madrigal Pharmaceuticals Inc. and Idera Pharmaceuticals Inc.

Meanwhile, Idera Pharmaceuticals Inc.’s average target price is $14, while its potential upside is 391.23%.

Institutional & Insider Ownership

Institutional investors held 93.3% of Madrigal Pharmaceuticals Inc. shares and 44.4% of Idera Pharmaceuticals Inc. shares. 3.5% are Madrigal Pharmaceuticals Inc.’s share held by insiders. Comparatively, 0.4% are Idera Pharmaceuticals Inc.’s share held by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders. Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD) Madrigal Pharmaceuticals Inc. -2.39% -46.33% -51.32% -58.79% 37.05% 22.99% Idera Pharmaceuticals Inc. -4.51% -28.7% -29.39% -57.51% -57.51% -61.14% For the past year Madrigal Pharmaceuticals Inc. had bullish trend while Idera Pharmaceuticals Inc. had bearish trend.


On 6 of the 8 factors Madrigal Pharmaceuticals Inc. beats Idera Pharmaceuticals Inc.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company’s lead candidate is MGL-3196, which is in Phase II clinical trials, a liver-directed thyroid hormone receptor-ß (THR-ß) agonist used for the treatment of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and familial hypercholesterolemia. It is also developing MGL-3745, which is in pre-clinical stage, a THR-ß agonist that is in preclinical trials. The company was founded in 2011 and is headquartered in West Conshohocken, Pennsylvania.

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States. It uses two drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and third-generation antisense (3GA) technology. The companyÂ’s drug candidates include IMO-2125, an agonist that is in Phase I/II clinical trials in combination with ipilimumab and pembrolizumab for the treatment of anti-PD-1 refractory metastatic melanoma and refractory solid tumors; IMO-8400, an antagonist, which is in Phase II clinical trial for the treatment of dermatomyositis. It also develops IDRA-008 for undisclosed liver target for rare disorder; 3GA compound for renal target; and IMO-9200, a drug candidate for potential use in selected autoimmune disease indications. In addition, the company is developing drug candidates to turn off the messenger RNA associated with disease causing genes. Idera Pharmaceuticals, Inc. has collaboration and license agreement with GSK to research, develop, and commercialize selected molecules from its 3GA technology for the treatment of selected targets in renal disease; collaboration with Abbott Molecular Inc. for the development of an in vitro companion diagnostic; and Merck & Co to research, develop, and commercialize vaccine products. The company was founded in 1989 and is based in Cambridge, Massachusetts.


Click Here to Continue...

Add a Comment

Your email address will not be published. Required fields are marked *